More than two-thirds of women classified as high-risk for breast cancer recurrence were safely spared chemotherapy after a ...

Next-generation sequencing is widely regarded as a transformative technology that delivers potentially life-prolonging therapies to patients with advanced cancers. Yet the testing is still underused ...

Experts discuss Prosigna-guided treatment decisions in high-risk early disease ...

For the more than 300,000 women diagnosed with breast cancer each year, one of the biggest challenges is uncertainty around treatment options. Treatment isn’t one-size-fits-all and often comes with ...

Patient-centered education and navigation support increase consent rates for genomic testing, aiding integration into cancer care and access to genomics-based trials. The SURGE study underscores the ...

Dr Tadross and colleagues were presented with the Royal College of Pathologists Achievement Award 2026 for Sustainability at ...

A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after ...

On-site automated NGS using circulating tumor DNA enabled comprehensive genomic testing in ~27 hours, substantially shortening the interval between diagnosis and potential targeted-therapy selection.

Vivek Subbiah, MD, considers artificial intelligence (AI) and comprehensive somatic and germline testing essential for guiding precision oncology and improving patient care. Vivek Subbiah, MD, chief ...

For Josh Henderson, 66, of Olympia, getting genetic testing was a no-brainer. “The first time I came to Fred Hutch, my oncologist suggested it,” said the retired IT manager who received a metastatic ...